<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278718</url>
  </required_header>
  <id_info>
    <org_study_id>MW2012-01-01</org_study_id>
    <nct_id>NCT02278718</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care</brief_title>
  <official_title>A Multicenter, Multinational, Randomized, Controlled, Open Label Study, Performed in Children With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid as Compared to Standard of Care (SOC) Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediWound Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MediWound Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a two-arms study intending to demonstrate superiority of NexoBrid
      treatment over SOC in children with thermal burns. The study objective is to evaluate the
      safety and clinical benefit of NexoBrid in hospitalized children (0-17 years) with deep
      partial and/or full thickness thermal burns of 1-30% TBSA and to compare NexoBrid to standard
      of care (SOC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 160 patients will be randomized into NexoBrid and SOC treatment (80 patients per
      arm).

      Age distribution will be managed as follows:

        -  45 patients 0-23 months old

        -  45 patients 24 months-3 years old

        -  30 patients 4-11 years old

        -  20 patients 12-17 years old The remaining 20 patients will be enrolled to any of the
           above groups, per their age during enrollment.

      The study will be conducted in three stages. In Stage I, at least 24 children age 4-18 years,
      hospitalized in burn units, with deep partial thickness burns ranging from 1%-30% TBSA, and
      who meet the entrance criteria, will be enrolled. Upon completion of stage I, a safety
      analysis will be performed on safety parameters and the results will be evaluated by a Data
      Safety Monitoring Board (DSMB) as defined in the agreed charter. If the DSMB does not have
      any safety concerns, Stage II will commence, this time enrolling at least 26 additional
      children aged of 1-18 years according to the study procedures. A DSMB will be convened to
      assess the safety data of the first 50 patients enrolled at stages 1 &amp; 2. If the DSMB has not
      found any safety concerns, stage III will commence in which patients from the age of birth to
      18 years will be included (stage III will include 110 remaining patients required to reach a
      total of 160 patients).

      Following the enrollment of a subject to the study and prior to randomization, physicians
      will define one or more Target Wounds (TWs) per subject according to TWs definition. All
      subjects' DPT and FT burns that fit the specified criteria are intended to receive study
      treatment per randomized study arm and therefore, must be designated as TWs.

      Prior to eschar removal treatment with NexoBrid or SOC subjects will be medicated with
      appropriate analgesia and undergo wound cleansing and dressing of all wounds with
      antibacterial solutions. Following wound cleansing and antibacterial treatments, subjects
      will undergo the eschar removal process as per treatment assignment (NexoBrid or SOC,
      following randomization). Subsequent to eschar removal, all wounds will be assessed and
      treated in the same manner, in accordance with post-eschar removal wound care strategy.
      Furthermore, subjects will undergo daily assessments (Vital signs (VS) and pain assessments)
      for one week and weekly assessments thereafter, until wound closure. Following wound closure,
      subjects will be followed up at 6 weeks, 12 weeks, and after that, at 6, 12, 18 and 24 months
      (for a blinded assessment of cosmesis, function and QoL evaluation).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Earlier eschar removal (in days)</measure>
    <time_frame>participants will be followed from randomization date and daily for the duration of hospital stay, an expected average of 3 weeks</time_frame>
    <description>Demonstrate superiority over SOC for eschar removal as measured by a survival analysis of incidence of complete eschar removal as a function of time. Eschar removal will be measured at the end of the debridement starting from randomization date.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Thermal Burns</condition>
  <arm_group>
    <arm_group_label>NexoBrid Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NexoBrid Gel is applied to the burn wound at a dose of 2g or 5g NexoBrid sterile powder mixed with 20g or 50g sterile Gel Vehicle per 180cm^2 of TBSA for four hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non surgical and Surgical Debridement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NexoBrid</intervention_name>
    <description>NexoBrid is an enzymatic debriding agent for Eschar Removal.</description>
    <arm_group_label>NexoBrid Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Surgical or Non-Surgical methods for Eschar Removal</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Stage 1: Males and females between 4 years to 18 years of age, Stage 2 (upon DSMB
             review): Males and females between 1 year to 18 years of age, Stage 3 (upon DSMB
             review): Males and females between 0 years to 18 years of age.

          2. Thermal burns caused by fire/flame, scalds or contact.

          3. Patient total burns area ≥ 1% DPT and / or FT,

          4. Patient total burns area should be ≤ 30% TBSA; SPT, DPT and/or FT in depth,

          5. Signed written informed consent by a legal guardian can be obtained within 84 hours of
             the burn injury.

        At least one wound (a continuous burn area which can be treated in one session; might
        include several anatomical areas) in a patient should meet all following criteria:

          1. Wound that is ≥ 1% TBSA (DPT and/or FT) (not including face, perineal or genital),

          2. Wound is composed of DPT and/or FT in depth. Superficial partial thickness areas may
             be included in the wound area only if cannot be separated from deeper areas (e.g.
             surrounded by or mixed with DPT areas) and might interfere with the treatment of the
             deeper areas,

          3. Wound that is potentially intended for surgical eschar removal,

          4. Wound's blisters can be unroofed, as judged by the investigator.

        Exclusion Criteria:

          1. Patients weighing less than 3kg,

          2. Patients who are unable to follow study procedures and follow up period,

          3. Patients with electrical or chemical burns,

          4. Patient with a continuous burn area above 15% TBSA,

          5. Patients with no DPT and/or FT burn area (only SPT wounds),

          6. Patient with circumferential anterior/posterior trunk fire/flame burns, &gt;15% TBSA
             (Circumferential is defined as encircling ≥ 80% of the trunk circumference),

          7. The following pre-enrolment dressings: a. Flammacerium, b. Silver Nitrate (AgNO3),

          8. Patients with diagnosed infections,

          9. Diagnosis of smoke inhalation injury,

         10. Patients with pre-enrolment wounds which are covered by eschar saturated with iodine
             or by SSD pseudoeschar (e.g. pseudoeschar as a result of &gt;12h SSD treatment),

         11. Patients with pre-enrolment escharotomy,

         12. Pregnant women (positive pregnancy test) or nursing mothers,

         13. Poorly controlled diabetes mellitus (HbA1c&gt;9%),

         14. Known Cardio-pulmonary disease, oxygen-dependent pulmonary diseases,
             broncho-pneumonia, uncontrolled asthma,

         15. Known conditions which interfere with circulation (peripheral vascular disease, edema,
             lymphedema, surgery to the regional lymph nodes, obesity),

         16. Any known conditions that would preclude safe participation in the study or adding
             further risk to the basic acute burn trauma (such as immuno-compromising diseases,
             life threatening trauma, severe pre-existing coagulation disorder,
             pulmono-cardiovascular, liver or neoplastic disease),

         17. ASA greater than 2

         18. Chronic systemic steroid intake,

         19. History of allergy and/or known sensitivity to pineapples, papaya, Bromelain or
             papain,

         20. Current (within 12 months prior to screening) suicide attempt,

         21. Enrollment in any investigational drug trial within 4 weeks prior to screening,

         22. Current (within 12 months prior to screening) alcohol (daily consumption &gt; 3 units for
             males and &gt;2 units for females) or drug abuse,

         23. Prisoners and incarcerated

         24. Patients who might depend on the clinical study site or investigator.

         25. Patient expresses objection to participate in the study.

         26. Patients with other severe cutaneous trauma at the same sites as the burns (i.e.
             blunt, avulsion or deep abrasion) or previous burn(s) at the same treatment site(s)

         27. General condition of patient would contraindicate surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lior Rosenberg, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>MediWound Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yaron Shoham, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>MediWound Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aya Ben Yaakov, Dr.</last_name>
    <phone>+972-77-971-4173</phone>
    <email>ayaby@mediwound.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keren David-Zarbiv</last_name>
    <phone>+972-77-9714103</phone>
    <email>kerend@mediwound.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maricopa Special Health Care District</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Foster, MD</last_name>
      <phone>602-344-5141</phone>
      <email>kevin_foster@dmgaz.org</email>
    </contact>
    <investigator>
      <last_name>Kevin Foster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Shawn Larson</last_name>
      <phone>352-273-8825</phone>
      <email>shawn.larson@surgery.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Pizano, MD</last_name>
      <phone>305-326-7065</phone>
      <email>LPizano@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of South Florida Board of Trustees</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Smith, Dr.</last_name>
      <phone>813-404-0057</phone>
      <email>Dsmith3@health.usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy Wibbenmeyer, MD</last_name>
      <phone>319-356-1304</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute, Inc.</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dhaval Bhavsar, MD</last_name>
      <email>dbhavsar@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>SC. Jessica Reynolds</last_name>
      <phone>913-588-0068</phone>
      <email>jreynolds11@kumc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Robert Sheridan</last_name>
      <phone>617-726-3575</phone>
      <phone_ext>4712</phone_ext>
      <email>rsheridan@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Singer, MD</last_name>
      <phone>631-444-7857</phone>
      <email>adam.singer@stonybrookmedicine.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Hospital &amp; Health Center dba Legacy Research Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mosier, MD</last_name>
      <email>mmosier@orclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Glat, Dr.</last_name>
      <phone>215-519-3695</phone>
      <email>PMG0804@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shawn Jekins Children's Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425s</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Lesher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah Health</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giavonni Lewis, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>S.C Suzy Slomiak</last_name>
      <email>Suzy.Slomiak@hsc.utah.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giavonni Lewis, MD</last_name>
      <phone>801-581-8990</phone>
      <email>Giavonni.Lewis@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tam Pham, MD</last_name>
      <phone>206-744-3140</phone>
      <email>tpham94@uw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Plastic Surgery</name>
      <address>
        <city>Gent</city>
        <zip>B 9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>S. Khechinashvili University Hospital</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guga Kashibadze, MD</last_name>
      <phone>95599172538</phone>
      <email>gugulil@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unfallkrankenhaus Berlin Zentrum für Schwerbrandverletzte mit Plastischer Chirurgie</name>
      <address>
        <city>Berlin</city>
        <zip>12683</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Sander, MD</last_name>
      <phone>030 5681 3501</phone>
      <email>frank.sander@ukb.de</email>
    </contact>
    <investigator>
      <last_name>Frank Sander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart - Olgahospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70176</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Raphael Staubach</last_name>
      <phone>+49 711 2785 5559</phone>
      <email>r.staubach@klinikum-stuttgart.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MRE Bethesda Gyermekkórháza</name>
      <address>
        <city>Budapest</city>
        <zip>H-1146</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruzsena Bene, Dr.</last_name>
      <phone>+36 1 422 2888</phone>
      <email>bene.ruzsena@bethesda.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>B.A.Z Megyei Kórház és Egyetemi Oktatókórház</name>
      <address>
        <city>Miskolc</city>
        <zip>H-3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rózsa Papp, Dr.</last_name>
      <phone>+36 20 553 5192</phone>
      <email>med-rose@freemail.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikai Kozpont Gyermekgyogyaszati Klinika</name>
      <address>
        <city>Pécs</city>
        <zip>H-7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamás Decsi, Prof.</last_name>
      <phone>+36 72 535 900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Ram Manohar Lohia Hospital, Baba Kharak Singh Marg</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krishna Rajendra Hospital</name>
      <address>
        <city>Mysuru</city>
        <zip>570001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vardhman Mahavir Medical College (VLCC) and Safdarjung Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitary Integrated Hospital Verona (AOUI Verona),</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasminka Minic, MD</last_name>
      <phone>00393487220710</phone>
      <email>minka27@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acute Burn Care &amp;Trauma Surgery, Dept Surgery/Burn Center, Rode Kruis Ziekenhuis, LUMC University Leiden</name>
      <address>
        <city>Beverwijk</city>
        <zip>1942</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Dzieciecy w Krakowie</name>
      <address>
        <city>Kraków</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Stanek, PhD</last_name>
      <phone>0048 12 658 20 11</phone>
      <phone_ext>1396</phone_ext>
      <email>bstanek@tlen.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Dzieciecy im.prof.dr.med Jana Bogdanowicza, Oddzial Chirurgii i Urologii Dzieciecej z Pododdzialem Leczenia Oparzen</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Jutkiewicz-Sypniewska, MD</last_name>
      <phone>0048 22 509 840 64 06</phone>
      <email>joasiajut@@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Joanna Jutkiewicz-Sypniewska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii &quot;Sfanta Maria&quot;</name>
      <address>
        <city>Iasi</city>
        <zip>700309</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Elena Hanganu</last_name>
      <phone>+4 0744709689</phone>
      <email>dr.elenahanganu@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta Tg- Mures</name>
      <address>
        <city>Târgu-Mureş</city>
        <zip>54000</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Gheorghe Ho Gozar</last_name>
      <phone>+4 0740070534</phone>
      <email>horea_gozar@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univerzitná nemocnica Bratislava, Klinika popálenin a rekonštrukčnej chirurgie</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>La Paz University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boulevar Sur s/n</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CNPE &quot;City clinical hospital of immediate and urgent medical aid n.a.Meshchaninov&quot; of Kharkiv CC and State institution 'Zaitsev V.T. Institute of general and urgent surgery of the National academy of medical sciences of Ukraine'</name>
      <address>
        <city>Kharkiv</city>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleksii Kravtsov, MD</last_name>
      <phone>+38 097 568 97 37</phone>
      <email>combustiolog7777@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal institution &quot;Odessa Regional Clinical Medical Center&quot;</name>
      <address>
        <city>Odesa</city>
        <zip>65049</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serhii Tatsyuk, MD</last_name>
      <phone>+380674863411</phone>
      <email>serg80404@ua.fm</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Children´s Hospital NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Yvonne Wilson</last_name>
      <phone>+44 121 333 8964</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Mamta Shah</last_name>
      <phone>0044 161 701 8140</phone>
      <email>Mamta.Shah@cmft.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Israel</country>
    <country>Sweden</country>
  </removed_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=nexobrid</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Rosenberg L, Krieger Y, Bogdanov-Berezovski A, Silberstein E, Shoham Y, Singer AJ. A novel rapid and selective enzymatic debridement agent for burn wound management: a multi-center RCT. Burns. 2014 May;40(3):466-74. doi: 10.1016/j.burns.2013.08.013. Epub 2013 Sep 26.</citation>
    <PMID>24074719</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 27, 2014</study_first_submitted>
  <study_first_submitted_qc>October 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2014</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

